- MDV3100
MDV3100 is an experimental
androgen receptor antagonist drug developed by the pharmaceutical companyMedivation for the treatment of Hormone-refractoryprostate cancer [ [http://investors.medivation.com/releasedetail.cfm?ReleaseID=231214 Medivation's MDV3100 Shown to Be Effective in a Preclinical Model of Hormone-Refractory Prostate Cancer] ] currently in Phase 1 clinical trials [ [http://clinicaltrials.gov/ct2/show?spons=%22Medivation%22&spons_ex=Y&rank=2 A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer] ] . Results so far have been encouraging; Medivation has reported up to an 89% decrease inprostate specific antigen serum levels after a month of taking the medicine [ [http://www.medicalnewstoday.com/articles/87762.php Medivation's MDV3100 Demonstrates Substantial PSA Reductions In First Patient Groups Treated In Phase 1-2 Hormone Refractory Prostate Cancer Trial] ] . Preliminary data from the Phase I/II study was presented at the 2008 meeting of the Americal Society of Clinical Oncology (ASCO).References
Wikimedia Foundation. 2010.